The UK and US have forged a key commercial pact that will maintain zero duties on UK medicine exports being sold in the American market.
The Terms of the Deal
As part of the deal, the UK has agreed to raise expenditure on drugs through the public health system. This move secures that tariffs on these vital goods will remain at zero for a timeframe of 36 months.
This deal follows recent threats to hike import taxes on patented drug imports, with potential rates floated as high as double the cost.
"This agreement between the Britain bolsters the international landscape for cutting-edge drugs and brings much-needed fairness to U.S.–U.K. drug exports," a release declared.
Trade Significance
Pharmaceuticals are one of the Britain's largest exports to the United States, which is clearly the primary destination for major companies like GSK and AstraZeneca.
Trade data show that in the one-year period leading up to last September, the UK shipped medicines valued at £11.1bn to the US. This amount made up nearly one-fifth of British export trade in that timeframe.
"This deal secures jobs, increases funding and facilitates the UK to establish itself as a worldwide center for biotech and pharma," a minister remarked.
Detailed UK Commitments
The deal includes several specific changes from the British government:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise overall health service expenditure on medicines from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The amount pharmaceutical firms must return to the NHS to prevent overspending will be limited at 15%. In the past, repayments topped twenty percent.
Industry Background
The pact follows a long-running dispute between the pharmaceutical industry and the UK government over spending levels and approval rates.
The disagreement were exacerbated by arguments that American customers were charged significantly more for the equivalent treatments than patients in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been halted or abandoned, while substantial expansions have been announced toward projects in the United States.
A senior figure stated that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had decreased as a proportion of its resources over the last ten years.
